Fast grower with 20.5% revenue growth trades at PEG of 4.8 while insiders complete their 10th straight quarter of selling.
This framework sees a fast grower transitioning from early to middle innings, where 20% growth at 63x earnings demands flawless execution that history suggests is unlikely.
What type of company is this, and what should we expect?
This framework classifies ISRG as a fast grower — Lynch's favorite category where 10-to-40-baggers live. The 20%+ revenue growth puts it squarely in this camp, though EPS growth lagging revenue growth suggests the fast-growing phase may be maturing.
Is the price fair for the growth we're getting?
Applying this lens reveals a PEG ratio near 5.0 — far above Lynch's preferred 1.0 threshold. The framework suggests paying 5x the growth rate is rarely rewarded, especially when treasuries offer 10x the earnings yield.
Are we early, middle, or late in this growth story?
This framework suggests early-to-middle innings — growth is still strong but margin compression and insider selling indicate the easy gains are behind us. The first-ever debt assumption at peak profitability signals a transition point.
Can you explain the growth in one sentence?
The growth story is clear: "They sell robots for surgery and the instruments surgeons need for each procedure." This framework values such clarity — the recurring instruments revenue from installed base creates predictable growth that an eleven-year-old could understand.
This framework sees a textbook fast grower entering the dangerous middle innings where growth rates justify any price until they don't. The business is excellent — robotic surgery with recurring revenue — but at 63x earnings with a PEG near 5.0, the easy money has been made. Lynch would note that insiders selling for 10 straight quarters while generating record cash flows suggests those closest to the business see limited upside. When treasury bills yield 10x more than this fast grower's earnings, what exactly are investors buying?
This analysis applies Peter Lynch's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Peter Lynch. Educational purposes only. Not financial advice.